Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-KIR3DL3 monoclonal antibody NPX267

A monoclonal antibody directed against human killer cell immunoglobulin-like receptor 3DL3 (killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 3; KIR3DL3), an inhibitory receptor for human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2; B7 homolog 7; B7-H7), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-KIR3DL3 monoclonal antibody NPX267 binds to KIR3DL3 expressed on T cells and natural killer (NK) cells and prevents the binding of KIR3DL3 to HHLA2 expressed on tumor cells. This abrogates the KIR3DL3/HHLA2-mediated inhibition of T-cell and NK-cell activation in the tumor microenvironment (TME), which may lead to enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response and NK cell cytotoxicity against cancer cells. HHLA2, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types. The KIR3DL3-HHLA2 pathway is an immunosuppressive pathway and a negative regulator of T-cell and NK-cell activation.
Code name:NPX 267
NPX-267
NPX267
Search NCI's Drug Dictionary